Loading organizations...
§ Private Profile · Jersey City, NJ, USA
Late-clinical stage biotechnology company developing topical oremepermin-α therapies for corneal wounds and ulcers.
Based in Jersey City, New Jersey, Claris Biotherapeutics is a late-clinical stage biotechnology company developing topical oremepermin-α therapies for corneal diseases, including wounds and ulcers. The enterprise focuses on targeted treatments for corneal repair by licensing intellectual property from the Massachusetts Eye and Ear Infirmary and partnering with Kringle Pharma for drug substance. Emerging from stealth mode in January 2024, the organization rapidly advanced its lead program from pre-investigational new drug stages to generating pivotal late-stage clinical data in four years. To support its advancing clinical pipeline, the firm raised $57 million in total Series A funding backed by a syndicate of prominent healthcare investors including Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors. Claris Biotherapeutics was founded in 2020 by Chief Executive Officer Clarke Atwell, Dr. Reza Dana, and Dr. Sunil Chauhan.
Claris Biotherapeutics has raised $57.0M across 1 funding round.
Claris Biotherapeutics has raised $57.0M in total across 1 funding round.
Claris Biotherapeutics has raised $57.0M across 1 funding round. Most recently, it raised $57.0M Series A in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 8, 2024 | $57M Series A | — | Agustin Mohedas, Mass General Brigham Ventures, Novo Holdings, RA Capital Management | Announced |
Claris Biotherapeutics has raised $57.0M in total across 1 funding round.
Claris Biotherapeutics's investors include Agustin Mohedas, Mass General Brigham Ventures, Novo Holdings, RA Capital Management.